Kirkeby Cell Therapy APS: Financial statements 2020
CVR: 38650165
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Kirkeby Cell Therapy APS (CVR 38650165) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 180,483 and a net result of DKK 183,657 compared with DKK 255,569 the year before. That is a decrease of 4.7% compared with the year before. Equity in the 2020 report amounted to DKK 1,295,773. The solvency ratio was 96%.
- Gross Profit
- DKK 180,483
- Profit/Loss
- DKK 183,657
- Equity
- DKK 1,295,773
- Total Assets
- DKK 1,349,967
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 180K | 184K | 1.3M | - |
| 2019 | - | 189K | 256K | 1.1M | - |
| 2018 | - | 120K | 71K | 937K | - |
Official annual report
How creditworthy is Kirkeby Cell Therapy APS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Kirkeby Cell Therapy APS has published its annual report for 2019. Gross profit came to DKK 189,347, and the net result was DKK 255,569.
About Kirkeby Cell Therapy APS
Kirkeby Cell Therapy APS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2017. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Kirkeby Cell Therapy IVS and Kirkeby Cell Therapey IVS. The management consists of Agnete Kirkeby. The company is owned by Agnete Kirkeby. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 25,872 and a net result of DKK -19,504 compared with DKK 111,159 the year before. Equity in the 2025 report amounted to DKK 1,541,351.